In addition, the elevated SRPX2 would inhibit the expression of AP1, and then attenuated SMAD7 expression, forming a positive feedback loop to enhance TGF-β/SMADs signaling, which could finally promote FMT and exacerbate pulmonary fibrosis. Here, SRPX2 is linked to pulmonary fibrosis.